Chiesi to Showcase Respiratory Leadership at ATS 2024

Chiesi USA, the U.S. arm of Chiesi Farmaceutici, an international healthcare group, has unveiled plans to present eight abstracts from its global respiratory research portfolio at the American Thoracic Society (ATS) 2024 International Conference in San Diego, scheduled from May 17-22, 2024. The company, which has a strong legacy in respiratory medicine, will highlight new data in asthma and chronic obstructive pulmonary disease (COPD), including six-month results from a single-inhaler triple therapy study for asthma and new pharmacokinetic studies of tanimilast, an inhaled phosphodiesterase-4 inhibitor, for COPD.

The conference will serve as a platform for Chiesi to demonstrate its commitment to innovation and its role as a significant sponsor of the annual ATS Research Program Benefit, aimed at supporting new researchers in respiratory disease. Carmen Dell’Anna, head of global medical affairs at Chiesi Group, emphasized the company's dedication to addressing respiratory-related challenges and creating shared value for both individuals and the planet.

Chiesi's presentations will cover various aspects of asthma and COPD. Notable among them is the anti-inflammatory effects of tanimilast in murine models of asthma and the positive impact of a single-inhaler triple therapy on lung function over six months in asthma patients. For COPD, the focus will be on the pharmacokinetics, safety, and tolerability of tanimilast in subjects with varying degrees of renal and hepatic impairment, as well as the effects of single-inhaler combinations on lung hyperinflation and exercise endurance.

Other respiratory conditions will also be explored, including the quality of home spirometry based on onsite spirometry quality, the development of a multi-biomarker assay for serum proteins by the Prognostic Lung Fibrosis Consortium, and a proteomic analysis of right ventricular hypertrophy in experimental pulmonary arterial hypertension.

Kenneth Mendez, president and CEO of the Asthma and Allergy Foundation of America, highlighted the importance of innovative medicines in providing tailored treatments for asthma and COPD, as well as addressing environmental factors contributing to respiratory diseases. He stressed the need for a multifaceted approach to bridge the gap in care and improve outcomes for patients.

In addition to its research presentations, Chiesi is actively engaging with the respiratory healthcare community by supporting early career investigator programs. The company is a Sapphire level sponsor of the Annual ATS Research Program Benefit and is funding a one-year research grant for a respiratory disease researcher to advance the understanding of obstructive lung disease.

Chiesi USA, based in Cary, North Carolina, specializes in commercializing products for hospital and office-based specialties. It is a subsidiary of Chiesi Farmaceutici S.p.A, a global pharmaceutical company headquartered in Parma, Italy. Chiesi USA focuses on therapies for acute cardiology, neonatology, cystic fibrosis, and rare diseases. Recognized as a Certified B Corporation™, Chiesi aims to enhance community health and well-being through its corporate social responsibility program, Chiesi in the Community.

Chiesi Group is a research-driven biopharmaceuticals company with a mission to improve people's quality of life and act responsibly towards society and the environment. As a certified B Corp, Chiesi strives to meet high standards of social and environmental impact and aims to achieve Net-Zero greenhouse gas emissions by 2035. The company operates in 31 countries, with over 6,500 employees and multiple research and development hubs worldwide.